EGFR and non-small cell lung carcinoma: Third‐generation EGFR‐TKIs, such as osimertinib, offer enhanced blood–brain barrier penetration and efficacy against both activating EGFR mutations (e.g., exon 19 deletions and 21 L858R) and the T790M resistance mutation, establishing them as a first‐line standard for EGFR‐mutant NSCLC with BMs [5, 6].